Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Dabigatran A4077: Reliable Thrombin Assays
2026-09-16
This scenario-based guide explains how Dabigatran, SKU A4077, can improve experimental control in thrombin inhibition and coagulation studies while avoiding common formulation and interpretation errors. It also clarifies the limits of extending coagulation findings into cell viability or cytotoxicity assays.
-
Shrimp STING Reveals an Ancestral DNA-Sensing Axis
2026-09-16
The reference study demonstrates that shrimp STING can recognize both cytosolic double-stranded DNA and cyclic dinucleotides, linking nucleic-acid detection to an IFN-like antiviral program. Its identification of a dsDNA–STING–IKKε–IRF–Vago4 axis expands current models of innate immune evolution and provides a framework for studying antiviral signaling in arthropods.
-
Reversible Surface Proteomics with Sulfo-NHS-SS-Biotin
2026-09-15
A mechanistic and translational guide to using Sulfo-NHS-SS-Biotin for reversible cell-surface labeling, affinity purification, and orthogonal validation of spatial protein interactions, with Notch receptor trafficking as a strategic case study.
-
Biotin (Vitamin B7) for Protein and Motor Assays
2026-09-15
A practical guide to using Biotin (Vitamin B7) across metabolic experiments, avidin-based detection, and protein-labeling controls. It also translates recent BicD–MAP7–kinesin findings into assay designs while separating true motor activation from biotin-enabled immobilization artifacts.
-
BAPTA-AM in Calcium-Dependent NMJ Assays
2026-09-14
BAPTA-AM is a cell-permeable calcium chelator for testing how intracellular Ca²⁺ controls localized BDNF release and neuromuscular junction assembly. This article translates recent NMJ findings into rigorous assay design while addressing optical, electrophysiological, and cytotoxicity-related confounders.
-
Sulfo-NHS-LC-Biotin Protocol Guide
2026-09-14
Sulfo-NHS-LC-Biotin provides a water-soluble method for covalently labeling accessible primary amines on proteins, peptides, and intact-cell surfaces. It is suited to permanent biotin capture and detection workflows, but not to reversible labeling or intracellular labeling of cells with an intact plasma membrane.
-
MiR-24-3p in Doxorubicin-Induced Heart Failure
2026-09-13
The reference study identifies a miR-24-3p/Sp1/PI3K regulatory axis that links doxorubicin-induced cardiomyocyte injury with apoptosis, oxidative stress, and impaired cardiac function. Its combined rat, cell, inhibitor, genetic-manipulation, and reporter-assay design provides a mechanistic framework for evaluating miR-24-3p silencing as a potential heart-failure strategy, while still requiring validation beyond experimental models.
-
Endogenous Melatonin, IRF3, and M1-Like Macrophages
2026-09-12
A 2024 Experimental Cell Research study shows that LPS stimulates macrophage melatonin production through the TLR4/TRIF/IRF3 axis and activates Aanat transcription. The findings position endogenous melatonin as a feedback mechanism that limits M1-like polarization, oxidative stress, and apoptosis during inflammatory activation.
-
LY2228820: Translational Control of p38 MAPK
2026-09-11
A mechanistic and strategic guide to using LY2228820, a selective p38 MAP kinase inhibitor, for target-engagement studies, anti-inflammatory research, cancer research, apoptosis assays, and multiomics-enabled translational decisions.
-
Metoprolol Research Workflows for Translational Assays
2026-09-11
Build reproducible beta1-receptor, cardiovascular, inflammation, and exploratory oncology assays with Metoprolol. This workflow connects concentration-response design and fresh-solution handling with pharmacokinetic lessons from tissue-distribution research.
-
How Kinase Inhibitors Tune p38α Dephosphorylation
2026-09-10
The reference study shows that selected kinase inhibitors can do more than occupy the p38α active site: they can reshape its activation loop to accelerate dephosphorylation by WIP1. This conformational mechanism offers a framework for designing inhibitors that combine direct kinase blockade with phosphatase-facilitated pathway shutdown.
-
Machine Learning Discovery of Senolytics
2026-09-10
The reference study shows that machine learning trained only on published screening data can identify senolytic candidates despite small, heterogeneous datasets. Computational screening followed by human-cell validation highlighted ginkgetin, periplocin, and oleandrin, offering a lower-cost framework for early-stage senolytic discovery.
-
LY2109761 and TGF-β Translation Strategy
2026-09-09
A mechanistic and translational guide to using LY2109761, a TGF-β receptor type I and II dual inhibitor, to connect receptor engagement with tumor plasticity, radiosensitivity, fibrosis, and reproducible experimental decision-making.
-
Norepinephrine–Angiotensin II Conversion in Shock
2026-09-09
The ARAMIS post-hoc analysis addresses a practical gap in vasodilatory shock: how to express norepinephrine exposure when angiotensin II is introduced. In 37 patients, the study estimated a median norepinephrine bitartrate-to-angiotensin II conversion dose ratio of 10:1, while finding no meaningful shift across baseline renin groups and a potentially lower ratio among patients previously exposed to angiotensin receptor blockers; these results are reported in the reference paper.
-
3-Deazaadenosine hydrochloride in SAHH Studies
2026-09-08
3-Deazaadenosine hydrochloride provides an upstream way to perturb SAHH-dependent methyl metabolism while researchers measure RNA stability, hepatic stellate cell activation, and fibrosis-associated phenotypes. This guide connects that biochemical lever to the IGF2BP1–TUBB4B–FAK model and offers practical dosing, controls, and troubleshooting strategies.